Key Findings:  The data provides a basis for further studies in evaluating the role of the cannabinoid and monoaminergic systems in the etiology of ASDs and whether the BTBR mice can model both schizophrenia and ASDs. The researchers note: "It is tempting to suggest the evaluation of Δ9-THC or other cannabinoids with reduced psychoactivity in irritability, tantrums and self-injurious behavior associated with autistic individuals."
Type of Study:  Animal Study
Study Result:  Positive
Research Location(s):  Spain, United States
Year of Pub:  2011
Cannabinoids Studied:  Tetrahydrocannabinol (THC)
Chemotype:  Chemotype I
Dosage: THC (1.0 and 10 mg/kg)
Route of Administration:  Injection
Citation:  Onaivi ES, et al. Consequences of cannabinoid and monoaminergic system disruption in a mouse model of autism spectrum disorders. Curr Neuropharmacol. 2011; 9:209-14. doi: 10.2174/157015911795017047
Authors:  Onaivi ES, Benno R, Halpern T, Mehanovic M, Schanz N, Sanders C, Yan X, Ishiguro H, Liu QR, Berzal AL, Viveros MP, Ali SF